Nystatin Orifarm 100 000 IU/ml oraalisuspensio Suomi - suomi - Fimea (Suomen lääkevirasto)

nystatin orifarm 100 000 iu/ml oraalisuspensio

orifarm generics a/s - nystatin - oraalisuspensio - 100 000 iu/ml - nystatiini

Buranagel 50 mg/g geeli Suomi - suomi - Fimea (Suomen lääkevirasto)

buranagel 50 mg/g geeli

orion corporation - ibuprofen - geeli - 50 mg/g - ibuprofeeni

Clindamycin Sanoswiss 150 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

clindamycin sanoswiss 150 mg kapseli, kova

sanoswiss uab - clindamycin hydrochloride - kapseli, kova - 150 mg - klindamysiini

Clindamycin Sanoswiss 300 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

clindamycin sanoswiss 300 mg kapseli, kova

sanoswiss uab - clindamycin hydrochloride - kapseli, kova - 300 mg - klindamysiini

Xefal 500 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

xefal 500 mg kapseli, kova

antibiotice sa - cefalexin monohydrate - kapseli, kova - 500 mg - kefaleksiini

Deflazacort Vital Pharma Nordic 30 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

deflazacort vital pharma nordic 30 mg tabletti

vital pharma nordic aps - deflazacort - tabletti - 30 mg - deflatsakorti

Deflazacort Vital Pharma Nordic 6 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

deflazacort vital pharma nordic 6 mg tabletti

vital pharma nordic aps - deflazacort - tabletti - 6 mg - deflatsakorti

Ambroxol ratiopharm 60 mg poretabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ambroxol ratiopharm 60 mg poretabletti

teva b.v. - ambroxol hydrochloride - poretabletti - 60 mg - ambroksoli

Lacosamide Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Lacosamide Adroiq Euroopan unioni - suomi - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.